Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium.
Terbach N, Shah R, Kelemen R, Klein PS, Gordienko D, Brown NA, Wilkinson CJ, Williams RS.
???displayArticle.abstract???
Valproic acid (VPA) is the most highly prescribed epilepsy treatment worldwide and is also used to prevent bipolar disorder and migraine. Surprisingly, very little is known about its mechanisms of cellular uptake. Here, we employ a range of cellular, molecular and genetic approaches to characterize VPA uptake using a simple biomedical model, Dictyostelium discoideum. We show that VPA is taken up against an electrochemical gradient in a dose-dependent manner. Transport is protein-mediated, dependent on pH and the proton gradient and shows strong substrate structure specificity. Using a genetic screen, we identified a protein homologous to a mammalian solute carrier family 4 (SLC4) bicarbonate transporter that we show is involved in VPA uptake. Pharmacological and genetic ablation of this protein reduces the uptake of VPA and partially protects against VPA-dependent developmental effects, and extracellular bicarbonate competes for VPA uptake in Dictyostelium. We further show that this uptake mechanism is likely to be conserved in both zebrafish (Danio rerio) and Xenopus laevis model systems. These results implicate, for the first time, an uptake mechanism for VPA through SLC4-catalysed activity.
Adkison,
Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter.
1996, Pubmed
Adkison,
Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter.
1996,
Pubmed Alper,
How pH regulates a pH regulator: a regulatory hot spot in the N-terminal cytoplasmic domain of the AE2 anion exchanger.
2002,
Pubmed Baltes,
Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays.
2007,
Pubmed Berridge,
Neural and developmental actions of lithium: a unifying hypothesis.
1989,
Pubmed Björnsson,
Hepatotoxicity associated with antiepileptic drugs.
2008,
Pubmed Boeckeler,
The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum.
2006,
Pubmed Bokelmann,
Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins.
2008,
Pubmed Brouwer,
Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats.
1993,
Pubmed Calabresi,
Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms.
2007,
Pubmed Chang,
Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers.
2001,
Pubmed Chapman,
Mechanism of anticonvulsant action of valproate.
1982,
Pubmed Chen,
The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
1999,
Pubmed Deuticke,
Discrimination of three parallel pathways of lactate transport in the human erythrocyte membrane by inhibitors and kinetic properties.
1982,
Pubmed Eickholt,
Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
2005,
Pubmed Emrich,
Therapeutic effect of valproate in mania.
1981,
Pubmed Faix,
A rapid and efficient method to generate multiple gene disruptions in Dictyostelium discoideum using a single selectable marker and the Cre-loxP system.
2004,
Pubmed Fischer,
Transport of valproate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: mechanism and substrate specificity.
2008,
Pubmed Gibbs,
Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
2004,
Pubmed Gögelein,
Flufenamic acid, mefenamic acid and niflumic acid inhibit single nonselective cation channels in the rat exocrine pancreas.
1990,
Pubmed Gonçalves,
Modulation of butyrate transport in Caco-2 cells.
2009,
Pubmed Gurvich,
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo.
2005,
Pubmed
,
Xenbase Izumi,
Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy.
2003,
Pubmed Jonathan Ryves,
GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.
2005,
Pubmed Kessel,
Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer.
2001,
Pubmed Koszela-Piotrowska,
Stilbene derivatives inhibit the activity of the inner mitochondrial membrane chloride channels.
2007,
Pubmed Lecona,
Kinetic analysis of butyrate transport in human colon adenocarcinoma cells reveals two different carrier-mediated mechanisms.
2008,
Pubmed Liu,
Altered expression of the 100 kDa subunit of the Dictyostelium vacuolar proton pump impairs enzyme assembly, endocytic function and cytosolic pH regulation.
2002,
Pubmed Löscher,
Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment.
1989,
Pubmed McNiff,
Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance.
1994,
Pubmed Mesdjian,
Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat.
1982,
Pubmed MEUNIER,
[Pharmacodynamic properties of N-dipropylacetic acid].
1963,
Pubmed Nakamura,
Proton gradient-dependent transport of valproic acid in human placental brush-border membrane vesicles.
2002,
Pubmed Ornoy,
Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.
2006,
Pubmed Ortwein,
Band 3, the anion exchanger of the erythrocyte membrane, is also a flippase.
1994,
Pubmed Pawolleck,
Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells.
2009,
Pubmed Phiel,
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
2001,
Pubmed
,
Xenbase Pushkin,
SLC4 base (HCO3 -, CO3 2-) transporters: classification, function, structure, genetic diseases, and knockout models.
2006,
Pubmed Romero,
The SLC4 family of HCO 3 - transporters.
2004,
Pubmed Siafaka-Kapadai,
Incorporation of [3H]valproic acid into lipids in GT1-7 neurons.
1998,
Pubmed Soll,
Stationary phase and the cell cycle of Dictyostelium discoideum in liquid nutrient medium.
1976,
Pubmed Tamai,
Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids.
1995,
Pubmed
,
Xenbase Terbach,
Structure-function studies for the panacea, valproic acid.
2009,
Pubmed Tian,
Valproic acid inhibits the depolarizing rectification in neurons of rat amygdala.
1994,
Pubmed Utoguchi,
Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line.
2000,
Pubmed Williams,
A common mechanism of action for three mood-stabilizing drugs.
2002,
Pubmed Williams,
Towards a molecular understanding of human diseases using Dictyostelium discoideum.
2006,
Pubmed Williams,
Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate.
1999,
Pubmed Yabuuchi,
Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter.
1998,
Pubmed
